Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2618 + Penpulimab + Anlotinib in Advanced HCC
NCT05975645Phase 1Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2023
- Primary completion
- Jun 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2618 in hepatocellular carcinoma (HCC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Overall Response Rate up to 2 years. Started Aug 2023; status: terminated.
02
Drugs
TQB2618
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05975645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05975645.